» Articles » PMID: 35563589

Obesity As a Risk Factor for Dementia and Alzheimer's Disease: The Role of Leptin

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 May 14
PMID 35563589
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity is a growing worldwide health problem, affecting many people due to excessive saturated fat consumption, lack of exercise, or a sedentary lifestyle. Leptin is an adipokine secreted by adipose tissue that increases in obesity and has central actions not only at the hypothalamic level but also in other regions and nuclei of the central nervous system (CNS) such as the cerebral cortex and hippocampus. These regions express the long form of leptin receptor LepRb, which is the unique leptin receptor capable of transmitting complete leptin signaling, and are the first regions to be affected by chronic neurocognitive deficits, such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD). In this review, we discuss different leptin resistance mechanisms that could be implicated in increasing the risk of developing AD, as leptin resistance is frequently associated with obesity, which is a chronic low-grade inflammatory state, and obesity is considered a risk factor for AD. Key players of leptin resistance are SOCS3, PTP1B, and TCPTP whose signalling is related to inflammation and could be worsened in AD. However, some data are controversial, and it is necessary to further investigate the underlying mechanisms of the AD-causing pathological processes and how altered leptin signalling affects such processes.

Citing Articles

Metabolically Healthy Obesity Is Characterized by a Distinct Proteome Signature.

Mir F, Abdesselem H, Cyprian F, Iskandarani A, Doudin A, Shraim M Int J Mol Sci. 2025; 26(5).

PMID: 40076884 PMC: 11901089. DOI: 10.3390/ijms26052262.


Identifying shared diagnostic genes and mechanisms in vascular dementia and Alzheimer's disease via bioinformatics and machine learning.

Zheng W, Lin D, Shi S, Ren J, Wu J, Wang M J Alzheimers Dis Rep. 2025; 8(1):1558-1572.

PMID: 40034343 PMC: 11863729. DOI: 10.1177/25424823241289804.


Leptin and Leptin Signaling in Multiple Sclerosis: A Narrative Review.

Flores-Cordero J, Aranaz-Murillo A, Vilarino-Garcia T, Perez-Perez A, Izquierdo G, Flores-Campos R Neuromolecular Med. 2025; 27(1):19.

PMID: 40019662 PMC: 11870953. DOI: 10.1007/s12017-025-08842-4.


Evidence from NHANES 2011-2014: a correlation between the weight-adjusted-waist index and cognitive abilities in the United States.

Zhao C, Xu X, Hao C Front Aging Neurosci. 2025; 17:1480609.

PMID: 39949539 PMC: 11821974. DOI: 10.3389/fnagi.2025.1480609.


Polymers for the treatment of Alzheimer's disease.

Zhu Y, Xu H, Yu C, Jiang W, Hou X, Ma M Front Pharmacol. 2025; 16:1512941.

PMID: 39944627 PMC: 11813879. DOI: 10.3389/fphar.2025.1512941.


References
1.
Kang S, Lee Y, Lee J . Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease. Yonsei Med J. 2017; 58(3):479-488. PMC: 5368131. DOI: 10.3349/ymj.2017.58.3.479. View

2.
Marques-Iturria I, Pueyo R, Garolera M, Segura B, Junque C, Garcia-Garcia I . Frontal cortical thinning and subcortical volume reductions in early adulthood obesity. Psychiatry Res. 2013; 214(2):109-15. DOI: 10.1016/j.pscychresns.2013.06.004. View

3.
Cheng L, Hu T, Shi H, Chen X, Wang H, Zheng K . DHA reduces hypothalamic inflammation and improves central leptin signaling in mice. Life Sci. 2020; 257:118036. DOI: 10.1016/j.lfs.2020.118036. View

4.
Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

5.
Ulker M, Kenangil G . The Relation of Circulating Levels of Leptin with Cognition in Patients with Alzheimer's Disease. Noro Psikiyatr Ars. 2018; 55(3):211-214. PMC: 6138232. DOI: 10.5152/npa.2017.16978. View